Format

Send to

Choose Destination
Neuropharmacology. 2018 Mar 15;131:424-430. doi: 10.1016/j.neuropharm.2018.01.002. Epub 2018 Jan 4.

Role of mGlu7 receptor in morphine rewarding effects is uncovered by a novel orthosteric agonist.

Author information

1
CNRS ERL 3649, Neuroplasticité et Thérapie des Addictions, Paris, France; INSERM UMR-S 1124, Paris, France; Université Paris Descartes, Paris, France.
2
Université Paris Descartes, Paris, France; CNRS UMR8601, Laboratoire de Chimie & Biochimie Pharmacologiques et Toxicologiques, Paris, France.
3
CNRS ERL 3649, Neuroplasticité et Thérapie des Addictions, Paris, France; INSERM UMR-S 1124, Paris, France; Université Paris Descartes, Paris, France. Electronic address: nicolas.marie@parisdescartes.fr.

Abstract

Opiate dependence is a major health issue and despite the existence of opioid substitution treatment, relapse frequently occurs. Group III metabotropic glutamate (mGlu) receptors has received much attention as a putative target in ethanol and cocaine addiction, but no data on opiate addiction exist. So we investigated the role of group III mGlu receptors in morphine rewarding effects through the expression and the reinstatement of conditioned place preference (CPP) using a newly synthesized mGlu4/mGlu7 receptor orthosteric agonist, LSP2-9166. We found that LSP2-9166 blocked morphine CPP expression and reinstatement after extinction. Blockade of CPP expression with LSP2-9166 was abolished when using XAP044, a mGlu7 antagonist. We also found that LSP2-9166 at the dose active for blocking morphine reward was devoid of any effect on locomotion, hedonic state, spatial memory, anxiety or depression. Altogether our data demonstrated that group III mGlu receptors, and more specifically mGlu7, might be a valuable target in opiate addiction.

KEYWORDS:

Addiction; Conditioned place preference; LSP2-9166; Morphine; mGlu7 receptor

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center